米诺环素联合比阿培南对头孢地尔耐药NDM肠杆菌的体外协同作用
本研究针对23株头孢地尔MIC≥16 mg/L的NDM型碳青霉烯酶肠杆菌临床分离株,采用棋盘法和时间杀菌曲线评估米诺环素-比阿培南联合的体外活性。结果显示96%(22/23)菌株呈协同作用,中位FICI为0.063,并在多种菌种和NDM变体中一致观察到协同与杀菌活性。
要点
- 米诺环素-比阿培南对头孢地尔耐药NDM肠杆菌协同率达96%(22/23)。
- 在米诺环素4 mg/L与比阿培南1 mg/L敏感折点浓度下,全部分离株生长受抑。
- 时间杀菌试验显示临床可达浓度组合下快速、暴露依赖性杀菌活性。
核心结论
- 米诺环素-比阿培南联合对头孢地尔耐药的NDM肠杆菌在多种菌种和NDM变体中表现一致的体外协同和杀菌活性。
- 结果支持将该联合方案作为头孢地尔治疗失败感染的潜在选择,进一步开展药效学与转化研究。
研究设计与样本
- 体外研究,纳入23株非重复临床NDM肠杆菌分离株,头孢地尔MIC≥16 mg/L(参考肉汤微量稀释法,铁缺乏阳离子调整Mueller-Hinton肉汤)。
- 采用棋盘法检测联合活性(FICI、亚MIC相互作用分析和累积抑制热图),并用3株代表性NDM-1或NDM-5产酶株进行时间杀菌试验。
主要发现
- 单药敏感率:米诺环素52%,比阿培南13%。
- 联合协同(FICI≤0.5)见于23株中22株(96%),中位FICI为0.063。
- 协同作用在Escherichia coli、Enterobacter cloacae和Klebsiella pneumoniae中一致观察到。
- 亚MIC分析显示不对称药效学相互作用,米诺环素暴露低至1/512×基线MIC时仍持续降低比阿培南MIC。
- 累积抑制热图显示在米诺环素4 mg/L和比阿培南1 mg/L敏感折点浓度下100%分离株生长受抑。
关键数值与推荐
- 头孢地尔耐药定义:MIC≥16 mg/L(参考肉汤微量稀释法)。
- 协同定义:FICI≤0.5;中位FICI为0.063。
- 单药敏感率:米诺环素52%,比阿培南13%。
临床怎么用
- 对头孢地尔耐药的NDM肠杆菌感染,米诺环素-比阿培南联合在体外显示高度协同,可考虑作为药敏指导下备选方案。
- 联合协同在临床可达浓度组合下即有表现,但需进一步药效学与临床转化验证后再常规应用。
局限性
- 为体外研究,仅23株临床分离株,尚无临床结局或动物模型数据。
- 时间杀菌试验仅采用3株代表性分离株(NDM-1或NDM-5)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cefiderocol is an important treatment option for infections caused by multidrug-resistant Gram-negative bacteria; however, resistance among New Delhi metallo-β-lactamase-producing Enterobacterales (NDME) is increasingly reported, leaving limited therapeutic alternatives. This study evaluated the in vitro activity of the minocycline-biapenem combination against cefiderocol-resistant NDME. METHODS: Twenty-three non-duplicate clinical NDME isolates with cefiderocol MIC ≥ 16 mg/L determined by reference broth microdilution in iron-depleted cation-adjusted Mueller-Hinton broth were analysed. Checkerboard assays were performed to assess combination activity using fractional inhibitory concentration indices (FICIs), sub-MIC interaction analysis and cumulative inhibition heatmaps. Time-kill assays were conducted using three representative isolates producing NDM-1 or NDM-5. RESULTS: Susceptibility rates for minocycline and biapenem tested alone were 52% and 13%, respectively. The minocycline-biapenem combination demonstrated synergistic activity (FICI ≤ 0.5) in 22 of 23 isolates (96%), with a median FICI of 0.063. Synergy was consistently observed across Escherichia coli, Enterobacter cloacae and Klebsiella pneumoniae. Sub-MIC analyses revealed asymmetric pharmacodynamic interactions, with sustained reductions in biapenem MIC at minocycline exposures as low as 1/512× baseline MIC. Cumulative inhibition heatmaps showed growth inhibition in 100% of isolates at the susceptible breakpoint concentrations of minocycline (4 mg/L) and biapenem (1 mg/L). Time-kill assays confirmed rapid and exposure-dependent bactericidal activity at clinically achievable concentration pairs. CONCLUSIONS: The minocycline-biapenem combination showed consistent in vitro synergistic and bactericidal activity against cefiderocol-resistant NDME across multiple species and NDM variants. These findings support further pharmacodynamic and translational evaluation of this combination as a potential therapeutic option for cefiderocol-refractory infections.
引用
- Okanda T, Nakajima N, Yamaguchi T, et al. In vitro synergistic activity of minocycline and biapenem against cefiderocol-resistant New Delhi metallo-β-lactamase-producing Enterobacterales. J Antimicrob Chemother. 2026. PMID: 41953962. doi:10.1093/jac/dkag128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。